Development of multivalent radioimmunonanoparticles for cancer imaging and therapy

Arutselvan Natarajan, Cheng Y. Xiong, Cordula Gruettner, Gerald L Denardo, Sally J. DeNardo

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: Noninvasive, focused hyperthermia can be achieved by using an externally applied alternating magnetic field (AMF) if effective concentrations of nanoparticles can be delivered to the target cancer cells. Targeting agents, for example, monoclonal antibodies or peptides, linked to magnetic iron oxide nanoparticles (NP), represent a promising strategy to target cancer cells and hyperthermia. Methods: We have developed a new radioconjugate NP ( 111In-DOTA-di-scFv-NP), using recombinantly generated antibody fragments, di-scFv-c, for the imaging and therapy of anti-MUC-1-expressing cancers, because aberrant MUC-1 is abundantly expressed on the majority of human epithelial cancers. Anti-MUC-1 di-scFv-c (50 kDa) were engineered, generated, and selected to link maleimide functionalized nanoparticles (NP-M). DOTA chelate was conjugated with di-scFv-c for radionuclide chelation to trace the radioimmunonanoparticles (RINPs) in vivo. Results: Heat-inducing NP-M were prepared with maleimide density >15 per particle for site-specific thiolation. The specific activity of the RINP was 4-5 μCi 111In/mg with >10 molecules of di-scFv per NP. We characterized the RINP by polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, size-exclusion chromatography, and tumor-cell binding. RINP had a >90% di-scFv conjugated to NP and an immunoreactivity >80% relative to unmodified di-scFv-c on HBT 3477 and DU145 tumor cells. Pharmacokinetics and whole-body autoradiography studies demonstrated that a 5% injecetd dose was targeted in tumor after 24 hours. Conclusions: Further development of this new preparation of RINP may provide uniquely high tumor-targeting NP for AMF-driven tumor hyperthermia with less spleen and kidney accumulation.

Original languageEnglish (US)
Pages (from-to)82-91
Number of pages10
JournalCancer Biotherapy and Radiopharmaceuticals
Volume23
Issue number1
DOIs
StatePublished - Feb 1 2008

Fingerprint

Nanoparticles
Neoplasms
Therapeutics
Fever
Magnetic Fields
Cellulose Acetate Electrophoresis
Immunoglobulin Fragments
Autoradiography
Radioisotopes
Gel Chromatography
Polyacrylamide Gel Electrophoresis
Spleen
Pharmacokinetics
Hot Temperature
Monoclonal Antibodies
Kidney
Peptides

Keywords

  • di-scFv-c
  • Immunoreactivity
  • Maleimide functionalization
  • MUC-1
  • Nanoparticle
  • Site-specific conjugation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. / Natarajan, Arutselvan; Xiong, Cheng Y.; Gruettner, Cordula; Denardo, Gerald L; DeNardo, Sally J.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 23, No. 1, 01.02.2008, p. 82-91.

Research output: Contribution to journalArticle

Natarajan, Arutselvan ; Xiong, Cheng Y. ; Gruettner, Cordula ; Denardo, Gerald L ; DeNardo, Sally J. / Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. In: Cancer Biotherapy and Radiopharmaceuticals. 2008 ; Vol. 23, No. 1. pp. 82-91.
@article{c148d8970ec24df7996d5ef25b7cf30a,
title = "Development of multivalent radioimmunonanoparticles for cancer imaging and therapy",
abstract = "Background: Noninvasive, focused hyperthermia can be achieved by using an externally applied alternating magnetic field (AMF) if effective concentrations of nanoparticles can be delivered to the target cancer cells. Targeting agents, for example, monoclonal antibodies or peptides, linked to magnetic iron oxide nanoparticles (NP), represent a promising strategy to target cancer cells and hyperthermia. Methods: We have developed a new radioconjugate NP ( 111In-DOTA-di-scFv-NP), using recombinantly generated antibody fragments, di-scFv-c, for the imaging and therapy of anti-MUC-1-expressing cancers, because aberrant MUC-1 is abundantly expressed on the majority of human epithelial cancers. Anti-MUC-1 di-scFv-c (50 kDa) were engineered, generated, and selected to link maleimide functionalized nanoparticles (NP-M). DOTA chelate was conjugated with di-scFv-c for radionuclide chelation to trace the radioimmunonanoparticles (RINPs) in vivo. Results: Heat-inducing NP-M were prepared with maleimide density >15 per particle for site-specific thiolation. The specific activity of the RINP was 4-5 μCi 111In/mg with >10 molecules of di-scFv per NP. We characterized the RINP by polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, size-exclusion chromatography, and tumor-cell binding. RINP had a >90{\%} di-scFv conjugated to NP and an immunoreactivity >80{\%} relative to unmodified di-scFv-c on HBT 3477 and DU145 tumor cells. Pharmacokinetics and whole-body autoradiography studies demonstrated that a 5{\%} injecetd dose was targeted in tumor after 24 hours. Conclusions: Further development of this new preparation of RINP may provide uniquely high tumor-targeting NP for AMF-driven tumor hyperthermia with less spleen and kidney accumulation.",
keywords = "di-scFv-c, Immunoreactivity, Maleimide functionalization, MUC-1, Nanoparticle, Site-specific conjugation",
author = "Arutselvan Natarajan and Xiong, {Cheng Y.} and Cordula Gruettner and Denardo, {Gerald L} and DeNardo, {Sally J.}",
year = "2008",
month = "2",
day = "1",
doi = "10.1089/cbr.2007.0410",
language = "English (US)",
volume = "23",
pages = "82--91",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Development of multivalent radioimmunonanoparticles for cancer imaging and therapy

AU - Natarajan, Arutselvan

AU - Xiong, Cheng Y.

AU - Gruettner, Cordula

AU - Denardo, Gerald L

AU - DeNardo, Sally J.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Background: Noninvasive, focused hyperthermia can be achieved by using an externally applied alternating magnetic field (AMF) if effective concentrations of nanoparticles can be delivered to the target cancer cells. Targeting agents, for example, monoclonal antibodies or peptides, linked to magnetic iron oxide nanoparticles (NP), represent a promising strategy to target cancer cells and hyperthermia. Methods: We have developed a new radioconjugate NP ( 111In-DOTA-di-scFv-NP), using recombinantly generated antibody fragments, di-scFv-c, for the imaging and therapy of anti-MUC-1-expressing cancers, because aberrant MUC-1 is abundantly expressed on the majority of human epithelial cancers. Anti-MUC-1 di-scFv-c (50 kDa) were engineered, generated, and selected to link maleimide functionalized nanoparticles (NP-M). DOTA chelate was conjugated with di-scFv-c for radionuclide chelation to trace the radioimmunonanoparticles (RINPs) in vivo. Results: Heat-inducing NP-M were prepared with maleimide density >15 per particle for site-specific thiolation. The specific activity of the RINP was 4-5 μCi 111In/mg with >10 molecules of di-scFv per NP. We characterized the RINP by polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, size-exclusion chromatography, and tumor-cell binding. RINP had a >90% di-scFv conjugated to NP and an immunoreactivity >80% relative to unmodified di-scFv-c on HBT 3477 and DU145 tumor cells. Pharmacokinetics and whole-body autoradiography studies demonstrated that a 5% injecetd dose was targeted in tumor after 24 hours. Conclusions: Further development of this new preparation of RINP may provide uniquely high tumor-targeting NP for AMF-driven tumor hyperthermia with less spleen and kidney accumulation.

AB - Background: Noninvasive, focused hyperthermia can be achieved by using an externally applied alternating magnetic field (AMF) if effective concentrations of nanoparticles can be delivered to the target cancer cells. Targeting agents, for example, monoclonal antibodies or peptides, linked to magnetic iron oxide nanoparticles (NP), represent a promising strategy to target cancer cells and hyperthermia. Methods: We have developed a new radioconjugate NP ( 111In-DOTA-di-scFv-NP), using recombinantly generated antibody fragments, di-scFv-c, for the imaging and therapy of anti-MUC-1-expressing cancers, because aberrant MUC-1 is abundantly expressed on the majority of human epithelial cancers. Anti-MUC-1 di-scFv-c (50 kDa) were engineered, generated, and selected to link maleimide functionalized nanoparticles (NP-M). DOTA chelate was conjugated with di-scFv-c for radionuclide chelation to trace the radioimmunonanoparticles (RINPs) in vivo. Results: Heat-inducing NP-M were prepared with maleimide density >15 per particle for site-specific thiolation. The specific activity of the RINP was 4-5 μCi 111In/mg with >10 molecules of di-scFv per NP. We characterized the RINP by polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, size-exclusion chromatography, and tumor-cell binding. RINP had a >90% di-scFv conjugated to NP and an immunoreactivity >80% relative to unmodified di-scFv-c on HBT 3477 and DU145 tumor cells. Pharmacokinetics and whole-body autoradiography studies demonstrated that a 5% injecetd dose was targeted in tumor after 24 hours. Conclusions: Further development of this new preparation of RINP may provide uniquely high tumor-targeting NP for AMF-driven tumor hyperthermia with less spleen and kidney accumulation.

KW - di-scFv-c

KW - Immunoreactivity

KW - Maleimide functionalization

KW - MUC-1

KW - Nanoparticle

KW - Site-specific conjugation

UR - http://www.scopus.com/inward/record.url?scp=39749145048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749145048&partnerID=8YFLogxK

U2 - 10.1089/cbr.2007.0410

DO - 10.1089/cbr.2007.0410

M3 - Article

C2 - 18298332

AN - SCOPUS:39749145048

VL - 23

SP - 82

EP - 91

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 1

ER -